Existing and emerging technologies for tumor genomic profiling

Journal of Clinical Oncology

Volumn 31, Issue 15, 2013, Pages 1815-1824

  MacConaill, Laura E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; GENE LIBRARY; GENE MUTATION; GENE TECHNOLOGY; GENE TRANSLOCATION; GENOMICS; GENOTYPE; HUMAN; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SANGER SEQUENCING; SINGLE MOLECULE SEQUENCING; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; CHROMOSOME ABERRATION; EXOME; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; METHODOLOGY; MUTATION; NEOPLASM; TRANSLATIONAL RESEARCH;

CHROMOSOME ABERRATIONS; EXOME; GENE EXPRESSION PROFILING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

MLCS; MLOWN;

EID: 84880485943     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.5948     Document Type: Review

References (110)

1. de Klein A, van Kessel AG, Grosveld G, et al: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765-767, 1982
2. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293, 1973
3. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003
4. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
5. MacConaill LE, Campbell CD, Kehoe SM, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887, 2009
6. Chapman MA, Lawrence MS, Keats JJ, et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011
7. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
8. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
9. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
10. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
11. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
12. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
13. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011
14. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative highthroughput sequencing: A pilot study. Sci Transl Med 3:111ra121, 2011
15. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698, 2005
16. Sanger F, Coulson AR: A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94:441-448, 1975
17. Maxam AM, Gilbert W: A new method for sequencing DNA. Proc Natl Acad Sci U S A 74:560-564, 1977
18. Smith LM, Sanders JZ, Kaiser RJ, et al: Fluorescence detection in automated DNA sequence analysis. Nature 321:674-679, 1986
19. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001
20. Venter JC, Adams MD, Myers EW, et al: The sequence of the human genome. Science 291:1304-1351, 2001
21. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458:719-724, 2009
22. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
23. Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through secondgeneration sequencing. Nat Rev Genet 11:685-696, 2010
24. Bar-Eli M, Ahuja H, Gonzalez-Cadavid N, et al: Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood 73:281-283, 1989
25. Thomas RK, Baker AC, Debiasi RM, et al: High-Throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351, 2007
26. Dias-Santagata D, Akhavanfard S, David SS, et al: Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158, 2010
27. Su Z, Dias-Santagata D, Duke M, et al: A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 13:74-84, 2011
28. Arcila M, Lau CY, Jhanwar SC, et al: Comprehensive analysis for clinically relevant oncogenic driver mutations in 1131 consecutive lung adenocarcinomas. Mod Pathol 24:404a, 2011 (suppl 1; abstr 1721)
29. Arcila M, Lau C, Nafa K, et al: Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 13:64-73, 2011
30. Beadling C, Heinrich MC, Warrick A, et al: Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 13:504-513, 2011
31. Gonzalez-Angulo AM, Hennessy BT, Mills GB: Future of personalized medicine in oncology: A systems biology approach. J Clin Oncol 28:2777-2783, 2010
32. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center Initiative. Clin Cancer Res 18:6373-6383, 2012
33. Kallioniemi A, Kallioniemi OP, Sudar D, et al: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258: 818-821, 1992
34. National Human Genome Researce Institute: DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). February 11, 2013 www.genome.gov/sequencingcosts
35. Sudol M, Fritz JL, Tran M, et al: Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: Application to a library of 50, 000 compounds. Antivir Chem Chemother 22:67-74, 2011
36. Margulies M, Egholm M, Altman WE, et al: Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380, 2005
37. Bentley DR, Balasubramanian S, Swerdlow HP, et al: Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53-59, 2008
38. Macconaill LE, Garraway LA: Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228, 2010
39. Quail MA, Smith M, Coupland P, et al: A tale of three next generation sequencing platforms: Comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13: 341, 2012
40. Liu L, Li Y, Li S, et al: Comparison of nextgeneration sequencing systems. J Biomed Biotechnol 2012:251364, 2012
41. Lam HY, Clark MJ, Chen R, et al: Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 30:78-82, 2012
42. Loman NJ, Misra RV, Dallman TJ, et al: Performance comparison of benchtop highthroughput sequencing platforms. Nat Biotechnol 30:434-439, 2012
43. Wold B, Myers RM: Sequence census methods for functional genomics. Nat Methods 5:19-21, 2008
44. Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72, 2008
45. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
46. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005, 2010
47. Shah SP, Morin RD, Khattra J, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809-813, 2009
48. Stephens PJ, McBride DJ, Lin ML, et al: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462:1005-1010, 2009
49. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
50. Fujimoto A, Totoki Y, Abe T, et al: Wholegenome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44:760-764, 2012
51. Campbell PJ, Stephens PJ, Pleasance ED, et al: Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40:722-729, 2008
52. Lee W, Jiang Z, Liu J, et al: The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473-477, 2010
53. Pleasance ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184-190, 2010
54. Pugh TJ, Weeraratne SD, Archer TC, et al: Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488: 106-110, 2012
55. Pleasance ED, Cheetham RK, Stephens PJ, et al: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196, 2010
56. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
57. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470:214-220, 2011
58. Leary RJ, Kinde I, Diehl F, et al: Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2:20ra14, 2010
59. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
60. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
61. Kohno T, Ichikawa H, Totoki Y, et al: KIF5BRET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012
62. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
63. Ju YS, Lee WC, Shin JY, et al: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22:436-445, 2012
64. Kostic AD, Gevers D, Pedamallu CS, et al: Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22: 292-298, 2012
65. Garraway LA, Baselga J: Whole-genome sequencing and cancer therapy: Is too much ever enough? Cancer Discov 2:766-768, 2012
66. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
67. Porreca GJ, Zhang K, Li JB, et al: Multiplex amplification of large sets of human exons. Nat Methods 4:931-936, 2007
68. Tewhey R, Warner JB, Nakano M, et al: Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol 27:1025-1031, 2009
69. Turner EH, Lee C, Ng SB, et al: Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods 6:315-316, 2009
70. Gnirke A, Melnikov A, Maguire J, et al: Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27:182-189, 2009
71. Sulonen AM, Ellonen P, Almusa H, et al: Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol 12:R94, 2011
72. Clark MJ, Chen R, Lam HY, et al: Performance comparison of exome DNA sequencing technologies. Nat Biotechnol 29:908-914, 2011
73. Asan, Xu Y, Jiang H, Tyler-Smith C, et al: Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol 12:R95, 2011
74. Parla JS, Iossifov I, Grabill I, et al: A comparative analysis of exome capture. Genome Biol 12: R97, 2011
75. Wagle N, Berger MF, Davis MJ, et al: Highthroughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82-93, 2012
76. Lonigro RJ, Grasso CS, Robinson DR, et al: Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 13:1019-1025, 2011
77. Wang Z, Gerstein M, Snyder M: RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 10:57-63, 2009
78. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793-798, 2010
79. Kinsella M, Harismendy O, Nakano M, et al: Sensitive gene fusion detection using ambiguously mapping RNA-Seq read pairs. Bioinformatics 27: 1068-1075, 2011
80. Maher CA, Kumar-Sinha C, Cao X, et al: Transcriptome sequencing to detect gene fusions in cancer. Nature 458:97-101, 2009
81. Maher CA, Palanisamy N, Brenner JC, et al: Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 106:12353-12358, 2009
82. Berger MF, Levin JZ, Vijayendran K, et al: Integrative analysis of the melanoma transcriptome. Genome Res 20:413-427, 2010
83. Mardis ER: ChIP-seq: Welcome to the new frontier. Nat Methods 4:613-614, 2007
84. Rudin CM, Durinck S, Stawiski EW, et al: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44:1111-1116, 2012
85. Peifer M, Fernández-Cuesta L, Sos ML, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104-1110, 2012
86. Ohshiro T, Matsubara K, Tsutsui M, et al: Single-molecule electrical random resequencing of DNA and RNA. Sci Rep 2:501, 2012
87. Branton D, Deamer DW, Marziali A, et al: The potential and challenges of nanopore sequencing. Nat Biotechnol 26:1146-1153, 2008
88. Schloss JA: How to get genomes at one ten-Thousandth the cost. Nat Biotechnol 26:1113-1115, 2008
89. Service RF: Gene sequencing: The race for the 1000 genome. Science 311:1544-1546, 2006
90. Schadt EE, Turner S, Kasarskis A: A window into third-generation sequencing. Hum Mol Genet 19:R227-R240, 2010
91. Eid J, Fehr A, Gray J, et al: Real-Time DNA sequencing from single polymerase molecules. Science 323:133-138, 2009
92. Braslavsky I, Hebert B, Kartalov E, et al: Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci U S A 100:3960-3964, 2003
93. Zwolak M, Di Ventra M: Electronic signature of DNA nucleotides via transverse transport. Nano Lett 5:421-424, 2005
94. Lagerqvist J, Zwolak M, Di Ventra M: Fast DNA sequencing via transverse electronic transport. Nano Lett 6:779-782, 2006
95. Lagerqvist J, Zwolak M, Di Ventra M: Influence of the environment and probes on rapid DNA sequencing via transverse electronic transport. Biophys J 93:2384-2390, 2007
96. Rajavelu A, Jurkowska RZ, Fritz J, et al: Function and disruption of DNA methyltransferase 3a cooperative DNA binding and nucleoprotein filament formation. Nucleic Acids Res 40:569-580, 2012
97. Scholz S, Liebler EK, Eickmann B, et al: Variation of the intercalating proline in artificial peptides mimicking the DNA binding and bending IHF protein. Amino Acids 43:289-298, 2012
98. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
99. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
100. Garraway LA, Jänne PA: Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2:214-226, 2012
101. Smith CC, Wang Q, Chin CS, et al: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263, 2012
102. Forshew T, Murtaza M, Parkinson C, et al: Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4:136ra68, 2012
103. Gysin S, Salt M, Young A, et al: Therapeutic strategies for targeting ras proteins. Genes Cancer 2:359-372, 2011
104. Flusberg BA, Webster DR, Lee JH, et al: Direct detection of DNA methylation during single-molecule, real-Time sequencing. Nat Methods 7:461-465, 2010
105. Ingolia NT, Ghaemmaghami S, Newman JR, et al: Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324:218-223, 2009
106. Kodama Y, Shumway M, Leinonen R: The Sequence Read Archive: Explosive growth of sequencing data. Nucleic Acids Res 40:D54-D56, 2012
107. Hsi-Yang Fritz M, Leinonen R, Cochrane G, et al: Efficient storage of high throughput DNA sequencing data using reference-based compression. Genome Res 21:734-740, 2011
108. Febbo PG, Ladanyi M, Aldape KD, et al: NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9:S1-S32, 2011 (suppl 5)
109. Levy MA, Lovly CM, Pao W: Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Res 22:2101-2108, 2012
110. Schrijver I, Aziz N, Farkas DH, et al: Opportunities and challenges associated with clinical diagnostic genome sequencing: A report of the Association for Molecular Pathology. J Mol Diagn 14:525-540, 2012